IMPORTANCE Cerebral microbleeds (CMBs) are collections of blood breakdown products that are a common incidental finding in magnetic resonance imaging of elderly individuals. Cerebral microbleeds are associated with cognitive deficits, but the mechanism is unclear. Studies show that individuals with CMBs related to symptomatic cerebral amyloid angiopathy have abnormal vascular reactivity and cerebral blood flow (CBF), but, to our knowledge, abnormalities in cerebral blood flow have not been reported for healthy individuals with incidental CMBs.
C erebral microbleeds (CMBs), which are small, ovoid, hypointense lesions seen on magnetic resonance imaging (MRI) sequences sensitive to susceptibility artifact, are the remnant of leakage of red blood cells from small cerebral vessels. The CMBs are noted in individuals with symptomatic intracerebral hemorrhage and Alzheimer disease, as well as in healthy elderly individuals. Cerebral microbleeds are associated with 2 types of small-vessel disease: cerebral amyloid angiopathy (CAA) and arteriosclerosis or lipohyalinosis (arteriosclerosis/lipohyalinosis). [1] [2] [3] [4] [5] [6] Cerebral amyloid angiopathy, characterized by buildup of β-amyloid (Aβ) in the wall of small vessels, primarily affects leptomeningeal and cortical vessels and is a cause of superficial microbleeds and lobar intracerebral hemorrhage. Arteriosclerosis/lipohyalinosis, attributed to hypertension and cardiovascular risk factors, primarily affects vessels in the basal ganglia and cerebral deep white matter and, with increasing severity, progresses to involve other brain regions.
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Population studies 5, 8, 9 show that CMBs are associated with age, smoking, diabetes mellitus, hypertension, lacunar infarcts, white matter disease, and APOE*4 (GenBank, 348; OMIM, 107741) carrier status. Some authors [10] [11] [12] [13] have reported that CMBs are associated with greater cognitive impairment or more rapid progression of Alzheimer disease; others 14 have found no such association.
The mechanism of how CMB-related small-vessel disease could contribute to cognitive deficits is uncertain. There have been several case-control studies that evaluated cerebral blood flow (CBF) in patients with symptomatic CAA. Participants with CAA were found to have impaired vascular reactivity on transcranial Doppler 15 and functional MRI 16, 17 in response to a visual task. Chung and colleagues 18 reported decreased regional resting-state CBF in people with CAA compared with those serving as controls, measured by singlephoton emission computed tomography. These studies suggested that impaired vascular reactivity or chronic hypoperfusion could contribute to neuronal damage and also could be a marker of disease severity. In this study, we extended the work described above and performed a cross-sectional evaluation of cognitively normal elderly individuals to test the hypothesis that the presence of incidental CMBs is associated with decreased CBF as measured by arterial spin-labeled MRI. We performed subset analyses on individuals with lobar and with cortical CMBs. Additional markers included cerebral metabolism, fibrillar Aβ, cognition, and indices of systemic and cerebral vascular disease.
Methods

Participants
Fifty-five cognitively normal individuals (mean [SD] age, 86.8 [2. 7] years) were recruited from an ongoing longitudinal cohort study 19 of very elderly individuals with normal cognition or mild cognitive impairment. This article includes all of the cognitively normal participants who had completed their initial testing when the present analysis was performed.
The University of Pittsburgh institutional review board approved this study. All participants completed written informed consent and received financial compensation. The study was conducted from May 1, 2010, to May 1, 2013 ; data analysis was performed between June 10, 2013, and April 9, 2015.
Neuropsychological Evaluation
Participants completed a battery of standard neuropsychological tests, described and cited in one reference. 20 Gradient-recalled echo resolution was 1 × 1 × 3 cm × 48 axial sections. Susceptibility-weighted imaging resolution was 0.6 × 0.5 × 1.5 cm × 96 sections for 14 participants and 0.6 × 0.5 × 1.2 cm × 72 sections for 17 individuals (the latter had incomplete infratentorial coverage). Identification criteria followed those described by Greenberg et al. 22 The location of CMB in the frontal, temporal, and parieto-occipital lobes was designated as cortical (cortical grey matter or grey and white matter junction) or subcortical white matter. Nonlobar CMBs were designated as being in deep subcortical structures (basal ganglia, thalamus, internal or external capsule), brainstem, or cerebellum. We used the Boston criteria 23 to identify a subset of participants with possible or probable CAA, which we refer to as the lobar CMB group. We also evaluated a subset of this lobar CMB group, the cortical CMB group (cortical CMBs defined above). A single reader (N.M.G.) performed all CMB identifications. The CMB assessment was performed with investigators blinded to all other variables. Interrater reliability assessment with an outside expert (M.E.G.) on a representative subset arterial spin-labeled and Pittsburgh compound B (PiB) PET values are the mean of the anterior cingulate, anterior ventral striatum, and frontal, lateral temporal, parietal, and precuneus cortex ROIs. The fluorodeoxyglucose PET posterior cortical index is the mean of the lateral temporal, parietal, and precuneus cortex ROIs. Arterial spin labeling was performed with the quantitative imaging of perfusion using a signal subtraction II procedure to measure CBF in units of milliliters per 100 grams of brain tissue per minute. 25 The hand-drawn ROIs were used to sample the CBF maps, which were normalized to the standardized Montreal Neurological Institute template via the SPM8 (Statistical Parametric Mapping; http://www.fil.ion.ucl.ac.uk /spm/) unified segmentation method. 26 Detailed MRI methods are available in the eMethods in the Supplement.
Positron Emission Tomography
Positron emission tomography was performed on an ECAT HR+ PET Scanner (CTI Molecular Imaging Inc) with a lead insert to reduce the contribution of scattered photons (Neuro-insert; PET Systems, CTI Molecular Imaging Inc) in 3-dimensional mode. Pittsburgh compound-B PET and fluorodeoxyglucose PET were performed as previously described. 24 Standardized uptake value ratios were generated relative to cerebellum. Detailed PET methods are presented in the eMethods in the Supplement.
Vascular Measures
A systemic vascular disease burden index was calculated by assigning 1 point each for (1) pathology noted on electrocardiogram, (2) ankle-brachial index less than 0.9, (3) common carotid stenosis greater than 25% determined using carotid Doppler, (4) common carotid intima-media thickness in the upper quintile, and (5) serum cystatin-C (measure of renal microvascular disease) in the upper tertile. The systemic vascular disease burden index was the sum of these points. Magnetic resonance imaging was used to determine a cerebrovascular disease burden index. White matter hyperintensities were evaluated with T2-weighted, fluidattenuated inversion recovery images and scored by a consensus of 2 raters (O.L.L., W.E.K.) who used a 0-to 9-point scale as was done previously in the Cardiovascular Health Study. 27 Infarcts were defined as lesions hyperintense on fluid-attenuated inversion recovery and hypointense on magnetization-prepared rapid gradient echo. The infarct assessment was performed by investigators blinded to participants' CMB status (O.L.L., W.E.K.). The cerebrovascular disease burden index was the summation of the white matter disease score and number of infarcts.
APOE Genotyping
DNA was isolated from blood (QIAmp Blood DNA Maxi Kit protocol; Qiagen). Genotypes for 2 APOE single-nucleotide polymorphisms-rs429358 (E*4) and rs7412 (E*2)-were determined using single-nucleotide polymorphism genotyping assays (TaqMan; Applied Biosystems).
Statistical Analysis
Statistical tests included the unpaired, 2-tailed t test for independent samples, Pearson correlation, χ 2 test, and Cohen d for effect size. All ROI analyses used multivariable linear regression models of age, sex, and global PiB standardized uptake value ratios except as noted. The assumptions for statistical tests were checked for violations and outliers. We used the Satterthwaite correction when variances were not equal for continuous outcomes, and we used the Fisher exact test for χ 2 testing when cell sizes were small. There were no analyses in which the P value gained or lost significance when outliers were removed, so the significance levels for the original analyses are reported. Bonferroni correction was used to account for multiple comparisons for ROI analyses and for neuropsychological tests. Voxelwise analyses were performed with and without linear regression of age, sex, global PiB standardized uptake value ratios, and false discovery rate control. False discovery rate control was performed at q = 0.05 [ie, 5% false-positives]). 28 Voxel-level analyses were performed within the SPM8 environment, and the remaining tests were calculated with SAS, version 9.3 (SAS Institute Inc). Statistical significance was defined as P < .05. ). There were no statistically significant differences between CMB(+) and CMB(−) individuals for variables noted in Table 1 , for the subcomponents of systemic vascular disease burden index, or for the years of education. Regarding the subcomponents of cerebrovascular disease burden index, there was a significant association between the presence of CMBs and infarcts (this is addressed further below); there was no association with white matter hyperintensities. Regarding neuropsychological testing, there was a trend toward an increased prevalence of nonzero CDR scores in individuals with CMBs; this association was not significant with Bonferroni correction for multiple neuropsychological tests (n = 14) (this is addressed further below). There were no consistent associations between CMBs and the results of other neuropsychological tests.
Results
Demographics
Cerebral Microbleed Topography
Cerebral microbleeds were present in 21 of 55 participants (38%) with a total of 54 CMBs. Ten individuals (18%) had only 1 CMB. A detailed description of CMB topography is given in the eTable in the Supplement. There were 43 lobar CMBs (20 cortical, 23 subcortical white), 5 deep subcortical and brainstem CMBs, and 6 cerebellar CMBs. Fourteen participants (25%) had CMBs exclusively in lobar regions, 3 participants (5%) had CMBs exclusively in deep or infratentorial regions (2 people had only cerebellar CMBs), and 4 participants (7%) had CMBs in both regions (3 people had only cerebellar CMBs in addition to lobar CMBs). Seventeen of 21 individuals (81%) with CMBs met the Boston criteria for possible or probable CAA. Evaluation of this CAA population was not significantly different from that of people with any CMBs. We also evaluated a subset of lobar CMBs: individuals with cortical CMBs (located in neocortical grey matter and grey-white junction; see Discussion). There were 11 of 55 participants (20%) with cortical CMBs for a total of 20 cortical CMBs.
Microbleeds and Vascular Pathology
Participants with any CMBs had a higher prevalence of infarcts: 5 of 21 (24%) CMB(+) and 2 of 34 (6%) CMB(−) participants (χ 2 P = .047). Individuals with cortical CMBs also had a higher prevalence of infarcts: 4 of 11 (36%) cortical CMB(+) and 3 of 44 (7%) cortical CMB(−) participants (χ 2 P = .010). There was no significant difference in white matter hyperintensities or the systemic vascular disease burden index or its components.
Microbleeds and CBF
Participants with any CMBs showed a trend toward decreased regional CBF compared with those without CMBs for both voxelwise and ROI analyses. The voxelwise data identified clusters in bilateral frontal and occipital lobes, the right temporal and parietal lobes, and the precuneus cortex, but the findings were not statistically significant when corrected for age, sex, and global PiB ( Figure, A and B) . The ROI data demonstrated reduced CBF in the frontal, parietal, and precuneus cortices and for the global mean after regression of covariates, but these reductions were not statistically significant with Bonferroni correction ( Table 2 ). In addition, the results were not significantly different for the lobar CMB subgroup.
When we compared CBF between participants with cortical CMBs with the rest of the cohort, we found significant reductions in CBF in voxelwise and ROI analyses after correction for covariates and multiple comparisons. Voxelwise analysis showed significant reduction in CBF in cortical and subcortical regions of all lobes as well as in deep structures 
Microbleeds and Fibrillar Aβ
Neither the presence nor the number of CMBs was significantly associated with fibrillar Aβ burden or APOE*4 genotype. In addition, the results were not significantly different for the lobar or cortical CMB subgroups.
Microbleeds and Brain Atrophy
Neither the presence nor the number of CMBs was significantly associated with hippocampal volume or ventricular volume. In addition, the results were not significantly different for the lobar or cortical CMB subgroups.
Microbleeds and Cognition
After consideration of the informant report and all neuropsychological testing, all participants in our study received a clinical consensus diagnosis of normal cognition, although several individuals had a CDR scale score of 0. 
Discussion
In this study of cognitively normal elderly individuals, we found that the presence of incidental CMBs in cortical regions, likely the result of CAA, is associated with significant and widespread reduction in resting-state CBF. The presence of any CMBs showed a trend toward reduced CBF, but this association did not reach statistical significance. This study extends the work of several groups that have shown impaired vascular reactivity and resting-state CBF in individuals with symptomatic CAA [15] [16] [17] [18] to the larger population of people with incidental CMBs. 5 Our findings suggest that asymptomatic elderly individuals with cortical CMBs are also exposed to chronic cerebral hypoperfusion, although no causal association can be inferred from the present data. However, this combination, which may reflect widespread CAA-related cerebrovascular dysfunction, could put these elderly individuals at risk for neuronal injury or cerebrovascular events. The cortical CMB group we evaluated is a subset of individuals with lobar CMBs who met the Boston criteria for possible or probable CAA. 23 We evaluated the cortical CMB group separately for several reasons: (1) the expectedly low mean number of incidental CMBs, (2) the fact that CAA initially affects leptomeningeal and cortical vessels, and (3) to increase the specificity for CAA since a surprisingly high proportion of our CMB(+) individuals (81%) met criteria suggesting CAA. In our participants with CMBs, the low CMB count (mean, 2) could have reduced the positive predictive value of lobar CMBs for CAA. There were widespread reductions in CBF in the cortical CMB group, but this result was not seen in participants with lobar CMBs. Possible explanations for the divergent findings are that a proportion of individuals with lobar white matter CMBs, but without cortical CMBs (included in the lobar CMB but not cortical CMB group), may have underlying arteriosclerosis/lipohyalinosis rather than CAA. Arteriosclerosis/ lipohyalinosis and CAA might have different effects on CBF owing to the distribution of blood vessels involved in each pathology. Normal cortex has relatively high CBF to supply the high metabolic activity of cortical grey matter. Cerebral amyloid angiopathy may have greater effects on CBF owing to its prominent involvement of superficial cortical blood vessels that supply the cortical grey matter. Alternatively, people with cortical CMBs may represent a unique subset of individuals with CAA who have greater CBF impairment for unclear reasons. We will evaluate these patients and repeat imaging 2 years after the present study and determine whether interval CMBs are consistent with CAA or arteriosclerosis or lipohyalinosis.
The cortical regions with the most significant reduction in CBF were the frontal, parietal, and precuneus cortices, with lesser but significant reduction in the occipital cortex on voxelwise analysis. Our result was unexpected given the posterior predominance of CAA-related vascular amyloid and several studies [15] [16] [17] that demonstrated impaired vascular reactivity in the occipital cortex. However, one of these vascular reactivity studies 16 showed that occipital resting-state CBF was not significantly reduced, and a single-photon emission computed tomography study of CBF 18 also did not find impairment in the occipital cortex. This finding suggests that CAA has widespread effects on blood flow involving both anterior and posterior regions. In addition, there could be differences in CMB-related regional impairment of vascular reactivity and resting-state CBF. Participants with CMBs had deficits shown on cognitive testing, but these associations were not significant after correction for multiple comparisons. All individuals met study criteria for normal cognition when neuropsychological tests and informant reports were considered. Individuals with any CMBs and those with cortical CMBs had trends toward a greater likelihood of having nonzero CDR scores. The CDR results for the cortical CMB group should be considered alongside the higher The association that we saw between CMBs and infarcts has been shown 5 in individuals with deep and infratentorial CMBs but not with CMBs attributed to CAA. There was no significant association between the presence or number of CMBs and cerebral metabolism; we did not find any evidence to suggest that neuronal hypometabolism is driving hypoperfusion. Longitudinal data will be important to evaluate for the development of hypometabolism. Limitations of this study include the relatively small sample size, the advanced age of the participants, and the crosssectional design. The most significant findings were in the group of patients with cortical CMBs. Although not a standard subgroup to evaluate, cortical CMBs are a subset of lobar CMBs and suggest underlying CAA. The data reported in this article are from the initial evaluation of an ongoing cohort study, and the longitudinal data will be critical to better understand the temporal relationships between CAA, cerebral small-vessel disease, CBF, cerebral metabolism, neurodegeneration, fibrillar Aβ, and cognition.
To our knowledge, this study reports several new findings that suggest directions for future work. Unlike prior studies [16] [17] [18] of CBF that tested individuals with symptomatic CAA, we looked at asymptomatic people with incidental CMBs. Research of other chronic progressive diseases, such as Alzheimer disease, has shifted toward early diagnosis and presymptomatic treatment. The widespread impairment in CBF shown in the present study suggests that presymptomatic diagnosis is important for understanding the progression of CAA and could be important for future therapies.
We also show the potential for resting-state CBF measured by arterial spin-labeled MRI to be a marker of CAA. Markers that reflect disease severity and that are modifiable over reasonably short time spans can help clarify disease progression and can be used as outcome markers for clinical trials. This was a small study, and more work is needed to evaluate CBF in larger studies of individuals with symptomatic and asymptomatic CAA and to test how CBF correlates with other markers of CAA, such as vascular Aβ, number of CMBs, symptomatic hemorrhage, and cognitive impairment.
Conclusions
This study indicates that, in asymptomatic elderly individuals, the presence of incidental cortical CMBs, likely the result of CAA, is associated with widespread reductions in resting-state CBF, cerebral infarcts, and subtle cognitive deficits. Early diagnosis of CAA and markers of disease severity-potentially resting-state CBF-could be key elements for understanding the pathophysiology of CAA and developing treatments. Longitudinal evaluation of the participants in this study will provide important information on the associations between CMB-related small-vessel disease, CBF, neurodegeneration, fibrillar Aβ, and cognition.
